Skip to main content
. 2020 Feb 25;77(6):357–367. doi: 10.1136/oemed-2019-105880

Table 1.

Total and 5 year interval relative frequencies of exposure assessment methods (EAM), and related study types, study locations, health outcomes and specificity of assessment in studies of occupational pesticide exposures and various health outcomes

Publication year 1993–2017 1993–1997 1998–2002 2003–2007 2008–2012 2013–2017 Missing
N % N % N % N % N % N % %
Number of articles 1271 100 152 12 224 17.6 274 21.6 289 22.7 332 26.1
Articles applying >1 EAM 203 16 29 19.1 19 8.5 51 18.6 54 18.7 50 15.1
Articles not reporting EAM 11 1.1 1 0.7 1 0.4 5 1.7 4 1.2
Number of EAM occurrences in studies n=1483 n=183 n=245 n=326 n=345 n=384
EAM: 0
Indirect EAM 1219 82.2 147 80.3 187 76.3 283 86.8 284 82.3 318 82.8
Direct EAM 253 17.1 35 19.1 58 23.7 42 12.9 56 16.2 62 16.1
EAM not reported 11 0.7 1 0.5 . 1 0.3 5 1.4 4 1
Indirect EAM:
Job title 182 12.3 26 14.2 43 17.6 35 10.7 41 11.9 37 9.6
Expert case-by-case 84 5.7 18 9.8 9 3.7 27 8.3 20 5.8 10 2.6
Self-reported exposure:
self-administered or
interview administered questionnaire
590 39.9 49 26.8 89 36.3 136 41.7 144 41.7 172 44.8
Self-reported job history:
self-administered or
interview administered questionnaire
103 6.9 16 8.7 11 4.5 20 6.1 26 7.5 30 7.8
Registers 85 5.7 20 10.9 15 6.1 24 7.4 11 3.2 15 3.9
JEM 69 4.7 4 2.2 11 4.5 9 2.8 14 4.1 31 8.1
CEM 3 0.2 3 0.8
TEM 1 0.1 1 0.3
Algorithm/model 80 5.4 9 4.9 3 1.2 26 8 26 7.6 16 4.2
Index 6 0.4 2 1.1 2 0.8 2 0.6
Score 1 0.1 1 0.4
Metric 1 0.1 1 0.5
Environmental monitoring 12 0.8 2 1.1 3 1.2 6 1.8 1 0.3
GIS 2 0.1 2 0.5
Direct EAM:
Biomonitoring:
Blood 175 11.8 24 13.1 43 17.6 32 9.8 39 11.3 37 9.6
Urine 69 4.7 9 4.9 13 5.3 8 2.5 16 4.6 23 6
Dermal 2 0.1 1 0.5 1 0.4
Hair 1 0.1 1 0.3
Adipose tissue 3 0.2 1 0.4 1 0.3 1 0.3
Personal air sampling 3 0.2 1 0.5 1 0.3 1 0.3
Specificity of EAM: 0.4
Job title 236 15.9 39 21.3 41 16.7 45 13.8 53 15.4 58 15.1
Pesticides in general 476 32.1 59 32.2 69 28.2 99 30.4 109 31.6 140 36.5
Type of pesticide 112 7.6 8 4.4 21 8.6 25 7.7 21 6.1 37 9.6
Chemical class 273 18.4 37 20.2 60 24.5 54 16.6 58 16.8 64 16.7
Specific active ingredient 380 25.6 40 21.9 54 22 102 31.3 100 29 84 21.9
Not reported 1 0.3 4 1.2 1 0.1
Study location of articles:* 0
LIC 17 1.1 3 1.2 4 1.2 10 2.6
LMIC 145 9.8 11 6 7 2.9 24 7.4 47 13.6 56 14.6
UMIC 222 15 14 7.7 31 12.7 37 11.3 55 15.9 85 22.1
HIC 1007 67.9 147 80.3 184 75.1 244 74.8 222 64.3 2018 54.7
SHIC 16 1.1 1 0.4 6 1.8 7 2 2 0.5
AHIC 36 2.4 4 2.2 4 1.6 7 2.1 4 1.2 17 4.4
Not reported 40 2.7 7 3.8 15 6.1 8 2.5 6 1.7 4 1
Study design of articles: 3
Cross-sectional 466 31.4 47 25.7 86 35.1 96 29.4 108 31.3 129 33.6
Cohort (prospective) 505 34.1 70 38.3 78 31.8 116 35.6 114 33 127 33.1
Cohort (retrospective) 20 1.3 5 2.7 5 2 3 0.9 4 1.2 3 0.8
Case-control 447 30.1 52 28.4 71 29 104 31.9 106 30.7 114 29.7
Health outcome in articles: 0
Self-reported outcomes 205 13.8 25 13.7 36 14.7 47 14.4 46 13.3 51 13.3
Cancer (doctor-diagnosed) 394 26.6 49 26.8 55 22.4 105 32.2 95 27.5 90 23.4
Genetic biomarkers (test results)† 184 12.4 12 6.6 35 14.3 35 10.7 48 13.9 54 14.1
Neurological (doctor-diagnosed) 94 6.3 8 4.4 10 4.1 21 6.4 28 8.1 27 7
Neurological (test results) 77 5.2 13 7.1 17 6.9 15 4.6 12 3.5 20 5.2
Reproductive+offspring (doctor-diagnosed) 97 6.5 14 7.7 13 5.3 17 5.2 17 4.9 36 9.4
Reproductive+offspring (test results) 76 5.1 4 2.2 23 9.4 16 4.9 18 5.2 15 3.9
Respiratory (doctor-diagnosed) 6 0.4 2 0.6 2 0.6 2 0.5
Respiratory (test results) 23 1.6 2 1.1 3 1.2 5 1.5 3 0.9 10 2.6
Mortality (all-cause) (doctor-diagnosed) 78 5.3 31 16.9 11 4.5 18 5.5 13 3.8 5 1.3
Other‡ 249 16.8 25 13.7 42 17.1 45 13.8 63 18.3 74 19.3

*Classification according to the World Bank Atlas Method, 2019.31 LIC=low-income countries. LMIC=lower middle-income countries. UMIC=upper middle-income countries. HIC=high-income countries. AHIC=multiple study locations all high-income countries. SHIC=multiple study locations some high-income countries.

†Refers to results from medical/diagnostic tests for a disease.

‡Miscellaneous outcomes with very low frequencies, for example, musculoskeletal disorders, suicide and diseases of the circulatory system.

AHIC, multiple study locations all high-income countries; CEM, crop exposure matrices; GIS, geographical information systems; HIC, high-income countries; JEM, job exposure matrices; LIC, low-income countries; LMIC, lower middle-income countries; SHIC, multiple study locations some high-income countries; TEM, task exposure matrices; UMIC, upper middle-income countries.